Metvix Krem 160 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metvix krem 160 mg/g

galderma nordic ab - methyl aminolevulinate hydrochloride - krem - 160 mg/g

Humulin NPH KwikPen Stungulyf, dreifa í áfylltum lyfjapenna 100 a.e./ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

humulin nph kwikpen stungulyf, dreifa í áfylltum lyfjapenna 100 a.e./ml

eli lilly danmark a/s - insulin human - stungulyf, dreifa í áfylltum lyfjapenna - 100 a.e./ml

Geepenil Vet. Stungulyfsstofn og leysir, lausn 24 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

geepenil vet. stungulyfsstofn og leysir, lausn 24 g

orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g

Sevelamerkarbonat WH Filmuhúðuð tafla 800 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sevelamerkarbonat wh filmuhúðuð tafla 800 mg

williams & halls ehf - sevelamerum karbónat - filmuhúðuð tafla - 800 mg

Nyvepria Evrópusambandið - íslenska - EMA (European Medicines Agency)

nyvepria

pfizer europe ma eeig  - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

SmofKabiven extra Nitrogen Innrennslislyf, fleyti Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

smofkabiven extra nitrogen innrennslislyf, fleyti

fresenius kabi ab - alaninum inn; argininum inn; glycine; histidinum inn; isoleucinum inn; leucinum inn; lysinum asetat; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; calcii chloridum dihydricum inn; natrii glycerophosphas; magnesium sulfate heptahydrate; kalii chloridum; natrii acetas; zinc sulphate heptahydrate; glucose monohydrate; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; fish oil rich in omega-3 acids - innrennslislyf, fleyti

Diclofenac Teva Hlaup 23,2 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

diclofenac teva hlaup 23,2 mg/g

teva b.v.* - diclofenacum tvíetýlamín - hlaup - 23,2 mg/g

Abasaglar (previously Abasria) Evrópusambandið - íslenska - EMA (European Medicines Agency)

abasaglar (previously abasria)

eli lilly nederland b.v. - glargíninsúlín - sykursýki - lyf notuð við sykursýki - meðferð sykursýki hjá fullorðnum, unglingum og börnum 2 ára og eldri.

Enviage Evrópusambandið - íslenska - EMA (European Medicines Agency)

enviage

novartis europharm ltd. - aliskiren - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - meðferð við nauðsynlegum háþrýstingi.

Kineret Evrópusambandið - íslenska - EMA (European Medicines Agency)

kineret

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - Ónæmisbælandi lyf - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret ætti að gefa í ásamt colchicine, ef viðeigandi. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).